List of Contract Research Companies in France - 21

Clean Cells is a GMP-licensed Contract Development and Manufacturing Organization providing R&D, production and quality control testing services to the biopharmaceutical industry. Our two-part site located in Western France holds an innovative process development platform, BSL2 and BSL3 GMP manufacturing laboratories and analytical areas to develop bespoke assays and perform GMP testing. Clean Cells is part of the Clean Biologics group and benefits from the additional experience of sister company Naobios, a CDMO with considerable experience in the development and manufacture of virus-based products.

Clean Cells is a GMP-licensed Contract Development and Manufacturing Organization providing R&D, production and quality control testing services to the biopharmaceutical industry. Our two-part site located in Western France holds an innovative process development platform, BSL2 and BSL3 GMP manufacturing laboratories and analytical areas to develop bespoke assays and perform GMP testing. Clean Cells is part of the Clean Biologics group and benefits from the additional experience of sister company Naobios, a CDMO with considerable experience in the development and manufacture of virus-based products.

CordenPharma is your full-service partner in the Contract Development & Manufacturing (CDMO) of APIs, Lipid Excipients, Drug Products and Packaging. Through a network of cGMP facilities across Europe and the US organized under six technology platforms – Peptides, Lipids & Carbohydrates, Oligonucleotides, Injectables, Highly Potent & Oncology, Small Molecules - CordenPharma experts translate complex ideas, processes and projects at any stage of development into high-value pharmaceutical products. Visit to learn more > cordenpharma.com

DavosPharma is a leading provider of discovery, chemistry, biology, and formulation services. We provide scientific expertise and technical and regulatory support during drug development for academic institutions, emerging biotech, and established multinationals. In an increasingly fragmented marketplace, DavosPharma strives to deliver the best solutions for your specific needs, timelines and budgets. We are unique in the industry because we are paid on deliverables, not ‘best effort'. DavosPharma has a 40 year track record of continuous success. Benefit from our experience and talent.

D.I.V.A. Expertise est une société de conseil, de stratégie et de développement en recherche scientifique dans les domaines de la Santé, de la Nutrition, de la Cosmétique et de l'Esthétique. Ses objectifs sont de soutenir les industriels dans la structuration, l'organisation et le développement de leur recherche afin d'optimiser ses coûts, délais et résultats. L'accompagnement personnalisé par nos experts dynamise le processus R&D d'un produit en promouvant Créativité, Innovation et Collaboration. Son cœur d'expertise est ciblé sur la biologie du tissu graisseux dit adipeux, reconnu comme organe endocrine avec un rôle fondamental et central sur l'homéostasie générale. Le partage de compétences, de valeurs scientifiques et humaines est à l'origine de la constitution de l'équipe de D.I.V.A. Expertise. A l'interface de quatre mondes Académique, Industriel, Médical et Chirurgical, D.I.V.A. Expertise a créé un réseau regroupant des experts multidisciplinaires et de renommée internationale dont elle assure l'animation et la coordination. D.I.V.A. Expertise (Développement, Innovation, Valorisation, Action en recherche) Ensemble, Embellissons la Recherche Pour plus d'informations, visitez notre site : www.diva-expertise.com Pour nous contacter, écrivez-nous : contact@diva-expertise.com

🔬 About ENTEROSYS At ENTEROSYS, we are science enthusiasts 🧪 driven by a conviction deeply rooted in medical history: for over two millennia, it has been acknowledged that the key to understanding many diseases lies in our digestive system and its interactions with other organs. Based on this ancient wisdom, we have embraced a modern and holistic approach focused on digestive physiology and the communication between the gut and peripheral organs. Specializing in the preclinical evaluation of compounds with therapeutic potential 💊, we utilize cutting-edge techniques to analyze physiological parameters in real time. Our unique expertise enables the development of proof of concept and precise study of the mechanisms of action of molecules aimed at preventing risk factors or treating diseases, including neurodegenerative 🧠 and metabolic disorders. Key Figures: Over 7️⃣ years of experience in preclinical CRO (Contract Research Organization) services 🔬. Over 7️⃣5️⃣% of clients are satisfied with our services and commission one or more additional studies 🤝. Over 5️⃣0️⃣0️⃣ scientific publications produced by the company's co-founders 📚. Our Services: Customized R&D projects 🗝️ to test therapeutic compounds. Innovative studies to differentiate in competitive markets 🚀. Revolutionary methods to speed up asset development 🛠️. A broad range of Unique Technologies: Accelerate the development of your assets with our revolutionary methods 🛠️. Diverse Testing: We provide a wide range of tests for the dermocosmetic 💄, nutraceutical 🌱, and pharmaceutical industries 🏥. Our Mission: To provide innovative preclinical solutions and advanced preclinical models to enhance and strategically position your molecules 💡. At ENTEROSYS, each client receives personalized support tailored to their specific needs 🎯.

DRUG DELIVERY SOLUTIONS - DRUG PRODUCT DEVELOPMENT - LICENSING-OUT OPPORTUNITIES Galenix provides a range of full R&D pharmaceutical services and Drug Delivery Solutions to health companies for fast access of their products on the market. ●●● From the sourcing of the API through the Drug Product development process, including preformulation, formulation, to clinical supplies, quality control, ICH stabilities and regulatory dossier submission for Europe and US FDA registration. Galenix provides its customers drug products “ready to launch” holding a Marketing Authorization. ●●● Galenix Innovations includes 6 different innovative technology platforms focusing on drug delivery solutions for life cycle management, new chemical entities and Biologicals using conventional medicinal presentations or its own patented technologies. « Patients are central to our approaches » Galenix team is focusing to preserve and/or to increase market shares on products through differentiation in accordance with regulations.

PEPTIDES, PEPTIDE LIBRARIES AND PROTEINS Innovative chemistry for therapeutic, diagnostic and cosmetic applications GENEPEP is a CRO company (with CIR agreement) focused on peptide synthesis & services : - Tools for nanoparticles & surface functionalization - Custom synthesis of peptides, proteins & peptide libraries - Catalog of toxins, peptides & pseudopeptides - Design & synthesis for SAR studies (optimisation of solubility, stability, efficacy,...) - Stability & solubility tests - Partner of European programs, ANR, FUI etc...

GenoSafe is a CRO providing analytical testing services for the evaluation of quality, safety and efficacy of Gene and Cell therapy candidates including : - GLP biodistribution, shedding and immunogenicity studies ; - QC testing, such as viral titration, safety and potency/efficacy testing ; - GCP bioanalysis of patient samples, including immunogenicity, shedding and gene expression studies. GenoSafe brings more than 15 years of experience in the development, qualification and validation of key analytical methods for product and sample testing.

Mabqi specializes in the discovery and development of human therapeutic antibodies. Our core technology is based on proprietary synthetic fully human libraries including pH-sensitive variants tailored for oncology applications. The company offers end-to-end discovery solutions, from antibody discovery, affinity maturation to optimization and full characterization, ensuring tailored support and delivery of high-quality and developable antibodies to meet your needs. Moreover, based on our know-how and technologies, Mabqi is committed to the discovery of therapeutic antibodies on innovative targets with off-the-shelf antibody assets available for partnered development and licensing opportunities.

Meddenovo offers a unique blend of AI technologies and molecular modeling to increase efficiency and success in drug development processes. Our technological platform, including bioAIM and focAlyze, delivers unparalleled drug candidate potency assessment and optimization of drug-like properties. In addition to designing small organic molecules, our proficiency in peptide-based medicine and metal chelators extends beyond traditional boundaries, offering a competitive advantage in creating solutions for novel drug research and development studies. In our integrated drug discovery services, we create a unique chemical space specific to your biological targets. We use our focAIyze module to explore druggability or any specific physiochemical property your project might need of the created chemical space. With our physics-based AI-supported software bioAIM, we screen the target with great accuracy. bioAIM, utilizing its unique blind docking capability, reveals precise binding sites and gauges the potency of molecules, ensuring compatibility with complex entities such as DNA or ribosomes. We also provide custom computational solutions using our modular tools to predict drug resistance bound to mutations, elucidate biochemical reaction mechanisms, and calculate metal affinity analysis. Meddenovo strives for precision and reliability in drug discovery, providing a refined approach to developing groundbreaking medicines with reduced failure rates and improved outcomes.

NEUROFIT, founded in 1996, is a pre-clinical CRO (Contract Research Organization) based in France and offering a comprehensive list of disease models and screening assays in the fields of psychiatry, neurology, multiple sclerosis, diabetes and pain. Neurofit works for major pharmaceutical and Biotech companies in Europe and the USA. Neurofit's core expertise in CNS and PNS includes animal behavior techniques, nerve conduction velocity measure, nerve fiber morphometry, primary neuronal cell cultures. Neurofit has long-standing experiences in psychiatric, neurodegenerative and autoimmune / inflammatory disorders. Our disease models are clinically relevant and predictive. Neurofit routinely performs, as part of a study, collection of blood, serum plasma, cerebrospinal fluid as well as dissection of brain microstructures from compound-treated animals to provide customers with useful samples for their pharmacokinetic, biochemistry and immunochemistry analyses.

Say yes to what's next! NextPharma, your CDMO partner for pharmaceutical development and manufacturing with fast, flexible and personalised solutions for worldwide markets. We are a leading European contract manufacturer in the pharmaceutical, nutraceutical, biotech and healthcare industries. For us, the most important step is always the next. Welcome to NextPharma! Because speed drives us, fills our working world with dynamism and allows us to grow. Our best recipe for joint success: space for passion. Because we are sure: Where excellent service inspires, passion is the best medicine. Our 2,300 European employees are located in our centres of excellence in Berlin, Bielefeld, Goettingen and Waltrop (Germany), Limay and Ploermel (France), Tampere (Finland), Edinburgh (UK) and Asker (Norway). NextPharma develops and produces a broad range of pharmaceutical dosage forms: • Solids (tablets, hard and soft capsules, powders, controlled-release pellets) • Non-sterile liquids (emulsions, suspensions, syrups, solutions) • Sterile liquids (ophthalmic and otic solutions and emulsions) • Semi-solids (creams, gels, ointments, suppositories) Special containment areas are available for: • Hormones (solid and semi-solid) • Narcotics (controlled substances) • Penicillin and Cephalosporin beta lactam antibiotics (solids and dry syrups) • Highly-potent compounds (soft gel and liquid-filled hard capsules) • Clinical trials services Career opportunities: Passion meets prospects! Joining NextPharma means taking the next step. A strong step forward. Because you will be adding prospects to your passion. With vision. Whether you are a school-leaver, an entry-level candidate, a specialist or an executive: the pharmaceutical, nutraceutical, biotech and healthcare industries are full of challenges and future potential. And it’s a future that we at NextPharma want to shape. Together with you! #speed #passion #service

We integrate standard assays on chip (eg. CRISPR, T-cell, cytotoxicity) to accelerate drug discovery from target to validation, and advance preclinical predictivity

OPM is a technological company specialized in precision medicine. OPM's mission is to bring innovative therapeutic and diagnostic solutions to treat therapeutic resistance and metastasis evolution. The patient is at the centre of our reflexion, of our unique innovative model, and our investments. For OPM "our collective success is paramount", there can be no value creation without exchange, without dialogue. The value creation resulting for us from reciprocity, i.e. balanced and fair exchanges at all levels, whether between internal collaborators, or with our partners, therapists, patients, experts and investors. To discuss partnership or investment, don't hesitate to get in touch : info@oncodesign.com

Oncodesign Services is a Contract research organization (CRO) specializing in drug discovery and preclinical services. Founded in 1995, Oncodesign Services mission' is to contribute to the discovery of innovative therapies with unmet medical needs, in particular in oncology, inflammation and infectious diseases. From target identification, hit-to-lead and lead optimization to IND filing, Oncodesign Services support the R&D programs of customers globally (whether pharmaceutical companies, biotechs, public research institutions, etc.). Oncodesign Services offers a full spectrum of services in medicinal chemistry, DMPK, pharmaco-imaging, bioanalysis, in vivo/In vitro pharmacology (including humanized models). This continuum enables, either as stand-alone (SOLO) or as integrated (DRIVE) programs, the drug discovery of small molecule, molecular radiotherapy and biologicals entities. As a pioneer in translational medicine to evaluate the efficacy of treatments, the company challenge relies on increasing throughput, minimizing timelines from bench to bedside while having a differential proposition of treatment for patients and therefore innovative science. For that, Oncodesign Services has been creating new technological pathways to find and select the best drug candidates. Oncodesign Services has BSL1, BSL2 and BSL3 laboratories and all sites maintain the full AAALAC international accreditation for our animal care and use program. Based in Dijon, France, in the heart of the university and hospital cluster, within the Paris-Saclay cluster and in Montreal, Canada, Oncodesign Services benefits from 15,000m² of fully equipped chemistry and biologic laboratories. Oncodesign Services has 230 employees in France, United Kingdom, Germany, Canada and the United States, with highly competent in discovery research and translational pharmacology.

OXELTIS is an independent medchem oriented service company managed by former researchers from Idenix Pharmaceuticals and located in Montpellier - France. Oxeltis is a company that delivers integrated solutions for managing and executing medicinal and fine organic chemistry projects. We run FTE programs (hit to lead optimization) with an expertise in some specialty chemistry such as macrocycles (pseudopeptides), mono & poly/oligosaccharides (sugar phosphates, iminosugars, saccharidic antigens…) nucleos(t)ides (modified nucleosides, phosphoramidites…), short peptides, linkers and PROTACs (Ligands E3 CRBN ligase library ) applied to discovery programs in oncology, antivirals and antibiotics mainly. OXELTIS client portfolio includes 40+ European and US companies from biotech to top 10 pharmaceutical companies. With its team of experienced medchem chemists, OXELTIS is proactive in providing rapid, high quality and competitive work. Specific expertise: - Contract research in medicinal chemistry, FTE programs for hit to lead optimization in different fields including antivirals, anticancer and antibiotics. - Fee-for-service custom synthesis expertise in heterocycles (in various fields), modified sugars (sugar phosphates, iminosugars, unnatural sugars…monosaccharides and oligosaccharides...), nucleoside/nucleotide (sugar and base-modified nucleosides, phosphoramidites…), macrocycles (e.g. antiviral antiproteases) . https://oxeltis.com/ https://twitter.com/Oxeltis_CRO

Prestwick Chemical is a French provider of smart libraries. For almost 20 years, the company, founded by Prof. Camille-Georges Wermuth, has provided medicinal chemistry services and screening libraries to accelerate small molecules drug discovery. Prestwick has a large portfolio of smart Libraries designed to ensure maximal chemical diversity, possibly to access new IP while remaining within reach of both low and high throughput screening processes. They are constantly updated and improved. Our clients have reported high quality hit generation rate. The Prestwick Chemical Library®, a unique collection of 1520 small molecules (95% of approved off-patent drugs) is our flagship and is mentioned in 400+ publications worldwide. New innovative collections continuously feed our portfolio: Our Prestwick Drug-Fragment library has been designed to optimize the chance of success in Hit finding using Fragment-based Drug Discovery. Prestwick Chemical became a brand of Greenpharma in 2021.

ProteoGenix is a leading life sciences organization which provides services in molecular biology and immunology and in particular polyclonal and monoclonal antibody development, recombinant protein expression and purification, peptide synthesis as well as gene synthesis. ProteoGenix’s commitment to its clients is to ensure the access to comprehensive and integrated solutions to help our customers develop the tools they need to efficiently conduct their biology and research projects in a time effective manner. Beginning with the synthesis of the gene ProteoGenix develops all the materials required for immunoassay services. Proteogenix’s exceptional and functional expertise combined with our extensive scientific knowledge and experience ensures ProteoGenix to be a reliable partner for your antibodies, proteins, genes (cDNA) and peptides. Our custom services ensure a unique and tailored process to our clients revolving around four areas : Protein expression and purification in E. Coli, Yeast, Insect cells (baculovirus) and Mammalian Cells Monoclonal antibody production and Polyclonal antibody production Gene synthesis, sub-cloning and mutagenesis Peptide synthesis, purification and conjugation ProteoGenix also provides the research and academic communities with a wide range of commercial products available on our website such as antibodies, proteins, ELISA kits, tissue microarrays, chimera RNAi, molecular biology products as well as many more.

Samabriva Biotechnology is a company that is creating a new method for producing biopharmaceuticals, chemicals, and biotech products using plants. Samabriva’s flexible platform combines the benefits of plant-based systems and traditional biomanufacturing techniques. By developing and cultivating high-yield plant clones in large-scale bioreactors it is possible to produce large quantities of high-value products more efficiently than traditional manufacturing methods.

Founded in 2019, backed by Y-Combinator, WhiteLab Genomics stands at the convergence of computer sciences and biology, pioneering the accelerated development of genomic medicines. By leveraging their proprietary technology, WhiteLab Genomics analyzes complex biological data powered by AI to significantly reduce development timelines and mitigate associated risks. Based on exhaustive datasets, the platform provides in-silico simulations to discover, and design optimized payloads and vectors. WhiteLab aims to expedite the drug development process, cut costs, and accelerate the delivery of life-saving therapies to the market. The company collaborates with leading pharmaceutical companies such as Sanofi, academic institutions, and innovative biotechnology companies. Recognized for their contribution to advancing the field of gene and cell therapy, WhiteLab Genomics is part of the prestigious French government supported by French Tech 2030 program and recently joined the Bayer Co.Lab in Cambridge, MA, and Ginkgo Bioworks' Technology Network, marking major milestones in our international expansion.